I had recommended staying away from the company for now because it looked too risky with a long wait before the company could complete its second phase 3 trial for pimavanserin...
Keep Reading →
April 11 - News
Investors love stocks that consistently beat the Street without getting ahead of their fundamentals and risking a meltdown.
Keep Reading →
April 9 - News
Is AstraZeneca plc (ADR) (NYSE:AZN) worth your attention right now? The smart money is becoming less confident. The number of long hedge fund bets fell by 2 lately.
Keep Reading →
April 8 - News
What doesn't J&J produce? From pharmaceuticals to consumer care goods to medical devices, this major medical player has it all.
Keep Reading →
April 7 - News
There are many promising biotech companies out there to choose from. One such company, named Vical Incorporated (NASDAQ:VICL), is targeting a cancer known as Melanoma.
Keep Reading →
April 4 - News
I follow quite a lot of companies, so the usefulness of a watchlist to me cannot be overstated.
Keep Reading →
April 3 - News
As I noted five weeks ago, cancer statistics are both staggering and disappointing.
Keep Reading →
April 2 - News
The drug, Invokana, the very first of its kind, was given the okay after nine clinical trials involving more than 10,000 patients with Type 2 diabetes.
Keep Reading →
April 2 - News
AbbVie Inc (NYSE:ABBV) investors should be aware of an increase in hedge fund sentiment of late, and we'll compare the company to peers like GlaxoSmithKline plc (ADR) (NYSE:GSK...
Keep Reading →
April 2 - News
The immune system doesn't generally attack tumors on its own. Immune cells are designed to attack foreign invaders but leave the human cells alone.
Keep Reading →
March 31 - News
Recently, with the loss of patents causing generic competition, the main attraction to pharmaceutical companies has been their dividend.
Keep Reading →
March 29 - News
It's been quite a while since we had a big wedding in the pharma world.
Keep Reading →
March 28 - News
According to most shareholders, hedge funds are seen as underperforming, old financial vehicles of yesteryear.
Keep Reading →
March 27 - News
For the last several years, Merck & Co., Inc.
Keep Reading →
March 26 - News
Normally, our weekly look at what's going on within the health-care sectors involves a mixture of health-care conferences, FDA panel meetings and decisions, and a plethora of ...
Keep Reading →
March 24 - News
NPS Pharmaceuticals, Inc. (NASDAQ:NPSP) is bringing its kids home.
Keep Reading →
March 22 - News
ACADIA Pharmaceuticals Inc.
Keep Reading →
March 22 - News
It’s almost here! Johnson & Johnson (NYSE:JNJ) is eagerly awaiting a decision on its type 2 diabetes drug Invokana (canagliflozin) by the end of the month.
Keep Reading →
March 22 - News
The demand for drugs worldwide is expected to increase due to emerging markets abroad and more specifically, due to an influx of demand from the aging "Baby Boomers" domestically...
Keep Reading →
March 20 - News
As I noted three weeks ago, cancer statistics are both staggering and disappointing.
Keep Reading →
March 20 - News
It's not uncommon for me to applaud the pharmaceutical industry as a solid long-term investment.
Keep Reading →
March 19 - News
Despite my recent obsession with Johnson & Johnson (NYSE:JNJ)'s restoration to health, I've long been a closet admirer of rival Pfizer Inc. (NYSE:PFE).
Keep Reading →
March 19 - News
What doesn't J&J produce? From pharmaceuticals to consumer care goods to medical devices, this major medical player has it all.
Keep Reading →
March 18 - News
With interest rates still sitting near record lows, investors looking for current income have been forced to move from fixed-income positions and into stocks to find yield.
Keep Reading →
March 18 - News
Global pharmaceutical giants AstraZeneca plc (ADR) (NYSE:AZN), Bristol Myers Squibb Co. (NYSE:BMY), and Eli Lilly & Co. (NYSE:LLY) meet most of the growth and profitability...
Keep Reading →
March 17 - Hedge Funds
The Motley Fool recently published its list of The 25 Best Companies in America and while Bristol-Myers Squibb Co.
Keep Reading →
March 12 - News
Flip to the 2012 financial results for AbbVie Inc (NYSE:ABBV) and you'll see that its best-selling drug, Humira, brought in $9.27 billion in 2012, or 51% of the company's total...
Keep Reading →
March 11 - News
Another day, another dollar, and another record high for the Dow Jones Industrial Average, which tacked on another 42-point gain yesterday, to bring the index to its highest levels...
Keep Reading →
March 8 - News
Gilead Sciences, Inc. (NASDAQ:GILD) is the world’s foremost biopharmaceutical company when it comes to combating deadly virus.
Keep Reading →
March 8 - News
Investing in the health care sector isn't easy.
Keep Reading →
March 7 - News
One thing's for sure: You'll never discover truly great investments unless you actively look for them.
Keep Reading →
March 7 - News
Eight months ago, Bayer and Johnson & Johnson (NYSE:JNJ) announced that the Food and Drug Administration had issued a complete response letter for their anticoagulant, Xarelto...
Keep Reading →
March 6 - News
Investing in the health care sector isn't easy.
Keep Reading →
March 5 - News
Gilead Sciences, Inc. (NASDAQ:GILD)' sofosbuvir with Johnson & Johnson (NYSE:JNJ) and Medivir's simeprevir are a match made in heaven.
Keep Reading →
March 5 - News
Do good things come in small packages for big pharma? Most of investors' attention is given to blockbuster drugs and drugs that have the potential to be blockbusters.
Keep Reading →
March 5 - News
If you don't religiously follow the markets and are just seeing the weekly results for the first time, it would appear that this past week was simply a slight winner and nothing...
Keep Reading →
March 4 - News
Mirror, mirror, on the wall, who's the frailest big pharma of all? The patent cliff has certainly taken its toll over the past couple of years, weakening several successful pharmaceutical...
Keep Reading →
March 1 - News
Are Bristol Myers Squibb Co. (NYSE:BMY) and Eli Lilly & Co.
Keep Reading →
February 25 - News
Shares of Novo Nordisk A/S (NYSE:NVO) are trying to recover from a recent sell-off that occurred after the FDA rejected its new drug Tresiba -- citing lack of a pre-approval ...
Keep Reading →
February 25 - News
A SWOT analysis is a look at a company’s strengths, weaknesses, opportunities, and threats, and is a tremendous way to gain a detailed and thorough perspective on a company ...
Keep Reading →
February 25 - Dividend Stocks
In the world of biotech stocks a lot of companies are starting to incorporate Hepatitis C treatments into their pipelines.
Keep Reading →
February 25 - News
A SWOT analysis is a look at a company’s strengths, weaknesses, opportunities, and threats, and is a great way to gain a detailed and thorough perspective on a company and its...
Keep Reading →
February 23 - News
Sanofi SA (ADR) (NYSE:SNY) announced this week that the Food and Drug Administration began to review the company's once-daily type 2 diabetes injectable lixisenatide.
Keep Reading →
February 21 - News
The Motley Fool's readers have spoken, and I have heeded your cries.
Keep Reading →
February 20 - News
Neither company has a stellar track record when it comes to dividends.
Keep Reading →
February 19 - Dividend Stocks
Pfizer Inc. (NYSE:PFE) recently spun off animal health firm Zoetis Inc (NYSE:ZTS) in the form of an IPO.
Keep Reading →
February 15 - News
Merck & Co., Inc. (NYSE:MRK) lost blockbuster asthma drug Singulair off the patent cliff last year, and the sales plunge quickly followed.
Keep Reading →
February 15 - News
Now more than ever, a comfortable retirement depends on secure, stable investments. Unfortunately, the right stocks for retirement won't just fall into your lap.
Keep Reading →
February 15 - News
At The Motley Fool, we poke plenty of fun at Wall Street analysts and their endless cycle of upgrades, downgrades, and "initiating coverage at neutral." Today, we'll show you ...
Keep Reading →
February 14 - News
LONDON -- Shares in Reckitt Benckiser Group Plc (LON:RB) lifted this morning following the group's positive fourth-quarter and full-year earnings release, with management declaring...
Keep Reading →
February 14 - News
